Enveric Biosciences, Inc. - Common Stock (ENVB)

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share. In a concurrent private placement, the Company issued unregistered series G warrants to purchase up to 328,802 shares of common stock and unregistered series H warrants to purchase up to 328,802 shares of common stock. The series G warrants have an exercise price of $4.16 per share, are exercisable immediately and will expire five years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The series H warrants have an exercise price of $4.16 per share, are exercisable immediately and will expire eighteen months after the effective date of a registration statement registering the shares issuable upon exercise of the warrants.

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered series G warrants to purchase up to 328,802 shares of common stock and unregistered series H warrants to purchase up to 328,802 shares of common stock. The series G warrants will have an exercise price of $4.16 per share, will be exercisable immediately and will expire five years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The series H warrants will have an exercise price of $4.16 per share, will be exercisable immediately and will expire eighteen months after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The closing of the offering is expected to occur on or about January 28, 2026, subject to the satisfaction of customary closing conditions.

The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives” (the “‘179 patent”), with claims to compositions and methods of treatment for novel molecules with the potential to be developed for mental health disorders.

The global financial landscape is witnessing a seismic shift as international corporations increasingly abandon their home markets to "onshore" in the United States. At the heart of this movement is Massachusetts, which has transformed from a regional innovation hub into a global "landing pad" for companies seeking to escape stagnant

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, respectively, at a reduced exercise price of $7.05 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (No. 333-284277) and Form S-3 (No. 333-290580). The gross proceeds to the Company from the exercise of the warrants were approximately $3.1 million, prior to deducting placement agent fees and estimated offering expenses.

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, respectively, at a reduced exercise price of $7.05 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (No. 333-284277) and Form S-3 (No. 333-290580). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.1 million, prior to deducting placement agent fees and estimated offering expenses.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company will present and participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 during “J.P. Morgan Week 2026” in San Francisco. Additionally, Enveric will attend Biotech Showcase 2026, which is being held from January 12-14, 2026.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM401 Series of molecules being developed as potential treatments for mental health disorders.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update.

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 12 pre-split shares. The reverse stock split will become effective at 8:00 a.m., New York time, on Tuesday, October 28, 2025. Enveric’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “ENVB” and will begin trading on a split-adjusted basis when the market opens on Tuesday, October 28, 2025.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of its 23rd patent from the United States Patent and Trademark Office (USPTO) for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental health disorders.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric’s issued U.S. Patent No. 12,138,276 (the’276 patent,) entitled, “Halogenated psilocybin derivatives and methods of using.”

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that its Board of Directors has authorized the Company’s Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury (DAT) strategy opportunities. Any such opportunities will be subject to further review and approval by the full Board.